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Abstract  
 
Background 
Evidence indicates that positive effects of 2-year early intervention for psychosis are not maintained 
after service withdrawal. Optimal duration of early intervention in sustaining initial improved 
outcomes remains to be determined.  
 
Aims 
To examine sustainability of positive effects of extended, 3-year early intervention for first-episode 
psychosis patients after transition to standard care. 
 
Method 
160 patients, who had received 2-year early intervention programme for first-episode psychosis, 
were enrolled to a 12-month randomised-controlled trial (NCT01202357) comparing 1-year 
extension of early intervention (3-year specialised treatment) with step-down care (2-year 
specialised treatment). Participants were followed up and reassessed 2 and 3 years after inclusion to 
the trial.  
 
Results 
There were no significant differences between the treatment groups in outcomes on functioning, 
symptom severity and service use during 2-year post-trial follow-up period. 
 
Conclusions 
Therapeutic benefits achieved by extended, 3-year early intervention were not sustainable after 
termination of specialised service.  
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Introduction 
 
Early intervention for psychosis has been the major focus in mental healthcare development 
worldwide in the past two decades.1 Literature has demonstrated superiority of early intervention 
services over standard care in improving outcomes of patients with first-episode psychosis.2-4 
However, considerable concern is raised regarding the sustainability of therapeutic benefits of early 
intervention for psychosis5,6 as there is evidence, albeit primarily based on two randomised-
controlled trials (RCTs),7-8 suggesting that positive effects achieved by early intervention may not 
be maintained after service withdrawal. In the Danish OPUS trial,9 the largest RCT thus far 
evaluating effectiveness of integrated early intervention service for psychosis, the findings of better 
symptom outcome and treatment adherence for early intervention over standard care at 2 years were 
no longer significant after 5 and 10 years of follow-up.7,10 Similarly, the British Lambeth Early 
Onset (LEO) study11,12 found that improved 18-month outcomes on functioning, quality of life and 
hospitalisation resulting from early intervention were not sustained at 5 years.8  
 
        Of note, one important possible explanation for the lack of sustained effect of early 
intervention is that 2-year specialized treatment (2 years in OPUS trial; 18 months in LEO trial) is 
insufficient to maintain superior outcomes in first-episode psychosis after transition to standard care. 
Until now, empirical research evaluating the effectiveness of longer-term early intervention for 
psychosis is scarce,4,13-15 and how long specialised treatment should be provided (usually offered for 
the first 1-2 years of illness) to consolidate and optimise the initial therapeutic gains remains 
unknown. One recently published RCT (namely OPUS II trial) comparing a 5-year extended early 
intervention with 2-year early intervention for first-episode psychosis has revealed lack of 
significant between-group difference in symptom and functional outcomes 5 years after service 
entry, though with higher client satisfaction and better working alliance in 5-year intervention group, 
as well as general improvement in clinical and functioning ratings for both groups over the follow-
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up period.15 There is no published RCT follow-up study examining the durability of positive effects 
of early intervention service with its treatment duration extended beyond 2 years. It is also worth 
noting that evidence supporting the effectiveness of early intervention for psychosis was mainly 
derived from Western countries. However, substantial variation across regions with respect to the 
content and intensity of early psychosis programmes, characteristics of patients enrolled and 
sociocultural contexts16 limits generalisability of results and precludes direct adoption of early 
intervention service model by non-Western countries, including some affluent Asian communities, 
where public mental healthcare is often over-burdened and under-resourced.17  
 
    Hong Kong is among the few cities in Asia to implement early intervention service for psychosis. 
The intervention programme Early Assessment Service for Young People with Psychosis (EASY) 
was launched in 2001 and comprises community-awareness programmes, an open referral system, 
and a 2-year specialised intervention for young people presenting with first-episode psychosis, 
followed by 1-year step-down care with preserved medical follow-up but no provision of case 
management.18 Evaluation of the EASY programme using historical-control methods showed that 
patients receiving early intervention had better functioning, milder symptom severity, fewer 
suicides and hospitalisations, and a lower disengagement rate than those in standard care, despite a 
lack of significant between-group difference in duration of untreated psychosis (DUP).19 In an 
attempt to evaluate effectiveness of longer-term early intervention for psychosis, we have 
conducted a RCT (EASY-Extension Trial) comparing a 1-year extension of early intervention 
service (i.e., 3-year early intervention) with step-down care (i.e., 2-year early intervention) in a 
representative cohort of Chinese young patients who had completed 2-year treatment in the EASY 
programme for their first-episode psychosis.13,20 This was the first reported RCT to provide 
evidence of the efficacy of extending an early intervention service for psychosis beyond 2 years. 
Our results indicated that patients receiving extended early intervention displayed significantly 
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better functioning, fewer negative and depressive symptoms, and lower treatment default rates than 
those managed by step-down care.13 
 
    In the current study, we aimed to address a critical question of the durability of therapeutic gains 
attained by extended early intervention for first-episode psychosis. To the best of our knowledge, 
this is the first RCT follow-up study examining the sustainability of beneficial effects of early 
intervention service with its treatment period extended beyond 2 years. Patients included in the 
EASY-Extension Trial were reassessed 1 and 2 years after completion of RCT to investigate 
whether better outcomes of the intervention group could be maintained after transition to generic 
psychiatric care.  
 
Method 
 
Participants 
This was a 3-year follow-up of a single-blind RCT (2 years after extended early intervention ended 
and 5 years after entry to the EASY programme) (online Fig. DS1, Fig. 1) comparing a 1-year 
extension of specialised early intervention (3-year early intervention) with a step-down care (2-year 
early intervention) in 160 patients who had received 2 years of care from early intervention service 
for first-episode psychosis.13 Participants were recruited from the EASY programme between 
November 2010 and August 2011 and underwent a 12-month clinical trial. Patients with DSM-IV21 
diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic 
disorder, delusional disorder, psychosis not otherwise specified, bipolar disorder with psychotic 
symptoms or depressive disorder with psychotic symptoms were included in the study. Exclusion 
criteria were intellectual disability, substance-induced psychosis, psychotic disorder due to general 
medical condition or an inability to speak Cantonese Chinese for research interview.  
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    Details of the EASY programme have been reported elsewhere.18 In brief, this is a publicly-
funded, territory-wide service providing comprehensive assessment and early intervention for 
individuals aged 15 to 25 years presenting with first-episode psychosis in Hong Kong.18 The service 
consists of five clinical teams with each covering a geographically-defined catchment area and 
comprising two psychiatrists, three case managers and one social worker. The programme adopts a 
phase-specific, case-management approach in which each patient is assigned a case manager who 
provides protocol-based psychosocial interventions,22 taking reference to the International Clinical 
Practice Guidelines for Early Psychosis23 with local cultural adaptations. This standardised 
intervention package is offered to all patients and their family caregivers with an aim to enhance 
psychological adjustment to early psychosis through in-depth engagement, comprehensive 
psychoeducation, adherence to medication treatment, coping and stress management, and relapse 
prevention.22 As case-loads of EASY case managers (approximately 1:80) are much heavier than 
that of those well-established early intervention services in the West, rather than providing intensive 
intervention such as cognitive-behavioral therapy (CBT) or specialised family therapy, case 
management of the EASY programme focuses on psychoeducation and supportive care. Emphasis 
is also placed on enhanced support and communications with family caregivers, who have a critical 
role in patient management, as most patients enrolled in the programme live with their families.18 
Family counseling and caregiver support groups are arranged if indicated. Patients with additional 
treatment needs such as presence of residual symptoms or secondary depressive symptoms are 
referred to clinical psychologists for provision of CBT. The programme also closely collaborates 
with non-governmental organisations (NGOs) which organise community-based rehabilitation 
programmes and vocational training for patients recovering from early psychosis. Multi-disciplinary 
case reviews are held on a regular basis to closely monitor patients’ clinical progress and treatment 
outcomes. Patients are assertively followed up for 2 years, after which they are managed by a 
transitional step-down clinic in the third year of treatment, whereby medical follow-up is offered by 
psychiatrists who have been responsible for their care in the 2-year programme but no case 
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management is provided (i.e., equivalent to standard psychiatric care but with 1-year continuous 
outpatient follow-up by psychiatrists of the EASY programme). They are then transferred to generic 
psychiatric services for continuous care. 
 
    In this study, participants were followed up and re-interviewed 2 and 3 years after inclusion to 
the trial. The study was approved by the local institutional review boards. All participants provided 
written informed consent. For those aged under 18 years, consent was also obtained from a parent 
or guardian. The trial was registered with ClinicalTrials.gov (NCT01202357). 
 
Randomisation  
Following baseline assessment, participants were randomly assigned in a 1:1 ratio to either 
extended early intervention (intervention group) or step-down care (control group) for the next 12 
months. An allocation sequence was computer-generated with a fixed block size of four. 
Randomisation and concealment procedures were conducted by an independent research staff who 
was not involved in recruitment, clinical management and research assessments of study 
participants. 
 
Treatment 
Participants in both treatment conditions were managed by psychiatrists from their respective 
EASY clinical teams during a 12-month period of RCT. After completion of the trial, all 
participants were transferred to standard psychiatric services for continuous care.  
 
Extended early intervention  
Specialised early intervention was continued in the form of an additional year of case management. 
A trained case manager took over cases from the EASY programme and was responsible for 
providing care and coordinating treatment with clinicians, allied health professionals and NGOs to 
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all participants in this group (n=82) (i.e., a case-load comparable to the EASY programme). Case 
management closely aligned with the EASY treatment protocols, focusing specifically on functional 
enhancement by assisting participants to re-establish supportive social networks, resume leisure 
pursuits and return to work. Additionally, continuous supportive care, psychoeducation, coping and 
stress management were delivered to family caregivers of each participant in the intervention group 
by the case manager. Biweekly clinical supervision was provided to case manager by senior 
psychiatrists who had extensive experience in early intervention for psychosis. 
 
Step-down care 
Step-down care provided outpatient medical follow-up with limited community support which 
focused mainly on crisis intervention. The two treatment groups did not differ from each other with 
respect to the intensity of medical follow-up by psychiatrists, prescription of antipsychotic 
medications and availability of various psychosocial interventions and community-based services. 
 
Assessment 
Diagnosis of each participant was ascertained in consensus meetings attended by a senior 
psychiatrist and research assistants using all available information encompassing the entire follow-
up period, including the Chinese-bilingual Structured Clinical Interview for DSM-IV (CB-SCID)24 
(conducted at baseline, 1 and 3-year follow-up), informant histories and medical records. Premorbid 
functioning was measured with the Premorbid Adjustment Scale (PAS)25 at study entry. The 
Interview for the Retrospective Assessment of the Onset of Schizophrenia (IRAOS)26 was employed 
at baseline to determine DUP, age and mode of onset of psychosis. Psychopathology was assessed 
at baseline, 1, 2 and 3-year follow-up using the Positive and Negative Syndrome Scale (PANSS)27 
and the Calgary Depression Scale (CDS).28 Psychosocial functioning was measured with the Social 
and Occupational Functioning Assessment Scale (SOFAS)29 and the Role Functioning Scale 
(RFS).30 The SOFAS provided global functioning estimate of an individual participant, whereas the 
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RFS, which comprised four subscales, was used to assess functional levels of various domains 
including work productivity, independent living and self-care, and immediate and extended social 
networks. Occupational status was also assessed. Functional evaluation was conducted at baseline, 
at 6 months, 1, 2, and 3 years after study entry.  
 
    Follow-up information on service use including hospitalisation, defaults in outpatient 
appointments and service disengagement, treatment characteristics including use of second-
generation antipsychotic and dose of antipsychotic medication (chlorpromazine equivalent doses31 
were computed for analysis), and other clinical outcome measures including relapse, all-cause 
mortality and suicide were obtained via systematic record review using outpatient and inpatient 
case-notes as well as computerised clinical information from the hospital database. Data on 
mortality and cause of death were also verified with the Coroner’s Register. Complete clinical 
record data over 2-year post-trial follow-up period were available to all participants for analysis. 
 
    Trained research assistants masked to treatment allocation administered all assessments. 
Videotaped interviews of 10 cases were independently rated by all research assistants for interrater 
reliability evaluation. Intra-class correlation coefficients (ICCs) for PANSS general 
psychopathology, positive and negative symptom subscales, and CDS total score were 0.92, 0.95, 
0.79 and 0.96, respectively, indicating good inter-rater reliability. Satisfactory level of concordance 
was also observed in functional measures, with ICCs for SOFAS and RFS total scores being 0.91 
and 0.86, respectively. 
 
Statistical analysis  
Statistical analyses were performed on an intention-to-treat (ITT) basis. Primary outcome was 
psychosocial functioning as measured by SOFAS and RFS. Secondary outcome measures included 
symptom severity, service use and other clinical variables. We estimated sample size based on 
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SOFAS as this was a key outcome measure of the study. To detect clinically meaningful 5-point 
difference in SOFAS, with a power of 0.8 and an alpha of 0.05, and to allow for 20% dropout rate, a 
total of 160 participants were required for the study. Potential attrition bias was examined by 
comparing between patients who participated in 3-year follow-up assessment and those who did not 
regarding sociodemographic factors, baseline clinical profiles, symptom and functional scores at 
entry, and treatment characteristics,. To determine group differences in functional and symptom 
outcomes during 2-year post-trial follow-up, a series of linear mixed models (LMMs) with repeated 
measures (using data from baseline and all follow-up time-points) were performed. Implementation 
of LMM analyses is recommended as a preferred statistical method of outcome analysis in clinical 
trials as these models can address missing outcome data by allowing the analysis of all available 
data on the assumption that data are missing at random.32 In our models, treatment group, time and 
group x time interaction were treated as fixed factors, and unstructured covariance structure was 
employed. Interaction terms between treatment group and time were used to estimate whether 
longitudinal changes of outcome variables across 3-year follow-up differed between the two groups. 
Between-group comparisons on functional and symptom outcomes at individual follow-up time-
points were analysed based on estimated mean differences and P values of difference derived from 
LMMs. In addition, comparisons between treatment groups based on completers-only analyses on 
functional and symptom outcomes at 2 and 3-year follow-up were conducted. Treatment 
characteristics, service use and other clinical outcome variables during 2-year post-trial follow-up 
were also compared between the two groups. DUP was log-transformed due to its skewed 
distribution. All statistical analyses were two-tailed with significance level set at P<0.05. Statistical 
analyses were performed with IBM SPSS Statistics 24.0.  
 
Results  
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The participant flow through the study is presented in Fig. 1. A total of 160 patients were enrolled 
and randomly assigned to intervention group (n=82) and control group (n=78). Table S1 shows 
baseline characteristics of 160 participants included in the trial and reveals no significant between-
group difference in sociodemographic profile or baseline clinical, functional and treatment 
characteristics. A total of 138 (intervention group: n=71, 86.6%; control group: n=67, 85.9%) and 
143 patients (intervention group: n=76, 92.7%; control group: n=67, 85.9%) participated in 2 and 3-
year follow-up assessment, respectively. There was no significant difference between the two 
groups in participation rate at 2-year (P=0.90) and 3-year (P=0.16) follow-up. For those who had 
completed 3-year follow-up, no significant between-group difference was observed in 
sociodemographic and other baseline characteristics (online Table DS2). Attrition analysis at 3-year 
follow-up demonstrated no significant difference between participants and non-participants in 
sociodemographic characteristics or baseline clinical, functional and treatment variables, with the 
exception of RFS immediate social network score (participants had higher scores than non-
participants, P=0.03). At the end of 3-year follow-up, 4 participants were deceased (intervention 
group: n=1; control group: n=3, P=0.36), with 2 died of suicide and 2 of natural causes (Fig. 1, 
Table 2).  
 
Functional outcomes 
Table 1 presents observed means (SDs) as well as estimated mean differences and P values of 
difference from LMMs at 1, 2 and 3-year follow-up for functional outcomes. There were no 
significant differences between the two groups in any of the functional measures at 2 and 3-year 
follow-up. Similarly, comparisons based on completers-only analyses demonstrated lack of 
significant between-group differences in ratings of all functional measures at 2 and 3-year follow-
up, with the exception that intervention group had significantly higher RFS extended social network 
score than control group at 2-year follow-up (online Table DS3). Longitudinal analysis over 3-year 
follow-up showed significant group x time interactions in SOFAS score (P<0.01), and RFS work 
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productivity score (P<0.01), independent living score (P<0.01) immediate social network score 
(P=0.03), extended social network score (P=0.01) and total score (P<0.01). This indicates that 
significant differential courses of functioning over 3 years in treatment groups appeared to be driven 
mostly by between-group differences in the first year of follow-up (i.e., a 12-month trial period). A 
graphical illustration of the longitudinal trajectories of functional measures across 3-year follow-up 
in treatment groups is shown in Fig. 2.  
 
Symptoms and other secondary outcomes 
Comparisons based on both LMMs and completers-only analyses revealed no significant 
differences between the two groups in outcomes on positive symptoms, negative symptoms, 
depressive symptoms and PANSS general psychopathology scores at 2 and 3-year follow-up (Table 
2, online Table DS4). There were no significant between-group differences in medication treatment 
characteristics, length of inpatient stay, employment outcome, and rates of relapse, psychiatric 
admission, outpatient treatment defaults and service disengagement across 2-year post-trial follow-
up period (Table 2).  
 
Discussion  
 
The aim of the current study was to examine the sustainability of superior functional and clinical 
outcomes of 1-year extended early intervention to step-down care (3-year versus 2-year early 
intervention service) in first-episode psychosis patients 1 and 2 years after the service ended. We 
found that there were no significant differences between the treatment groups in outcomes on 
functioning, symptom severity and service use during 2-year post-trial follow-up period. Although 
significant time x intervention interaction effects were observed across 3-year follow-up in various 
functional measures, these findings appeared to be driven mainly by group differences occurred in 
the first year of follow-up when extended specialised treatment was actively implemented. Our 
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results thus indicate that despite extending early intervention service to 3-year duration, superior 
outcomes achieved by specialised treatment still could not be maintained after transition to generic 
psychiatric service.  
 
    Of note, however, our negative findings concur with the results of two previous RCT follow-up 
studies, namely the OPUS and LEO trials7,8 which also failed to demonstrate sustained superiority 
of early intervention over standard care in most treatment outcomes after service withdrawal. 
Alternatively, despite lack of statistically significant between-group differences in functional ratings 
and employment outcome at post-trial follow-up, our results showed that patients randomised to 
intervention group exhibited higher scores than those allocated to control group in global 
functioning and most individual functional domains. Additionally, patients receiving extended early 
intervention attained higher full-time employment rate and longer cumulative duration in full-time 
work than those managed by step-down care by the end of 3-year follow-up. Hence, this indicates 
that, overall, the intervention group still compared favorably with the control group in longer-term 
functional outcome, with the former having slightly better functioning, albeit statistically 
nonsignificant, than the latter 2 years after service termination. It is also worth noting that although 
intervention group exhibited functional decline in RFS domains of social networks after service 
withdrawal, improvement in work productivity and independent living was largely maintained. 
Subsequent loss of significant group difference in functioning was also partly due to gradual 
functional improvement in control group during the post-trial follow-up.  
 
  Our findings, on the one hand, seem to support the proposition that positive effects of early 
intervention persist only as long as the service continues.33 This may further suggest that specialised 
treatment programmes do not alter the early course of illness in first-episode psychosis patients and 
hence lack the lasting influence on longer-term outcome. On the other hand, a number of factors 
might contribute to an apparent loss of therapeutic benefits attained by extended early intervention, 
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particularly on functional outcome, over the subsequent 2 years after transition to generic 
psychiatric care. First, it might be possible that 3-year duration of early intervention for psychosis is 
still insufficient to maintain initial functional gains after specialised service ended. Substantial 
evidence has also shown that a significant proportion of first-episode psychosis patients experience 
persistent functional impairment even in the presence of clinical remission.34-36 A longer period of 
early intervention encompassing the entire hypothesised critical period (i.e., up to 5 years after 
onset of psychosis)37 might be required to achieve sustained functional improvement (please refer to 
two RCTs evaluating effectiveness of 5-year early intervention service for psychosis, namely the 
Danish OPUS II trial and the Canadian trial).14,15 Second, treatment intensity level of our early 
intervention might be significantly compromised by a high patient-to-case manager ratio, rendering 
it inadequate to maintain longer-term beneficial effects. Conversely, as our service is constrained by 
low resources and high case-loads as compared to those well-established early psychosis 
progrmames implemented in some Western countries, our results should be generalised to other 
populations with caution. Third, recent enhancement of community psychiatric services in Hong 
Kong38 might, however, dilute the positive effect of extended intervention on longer-term outcomes 
through an overall improvement in treatment efficacy of generic psychiatric care received by 
participants during the post-trial period. This may in fact echo the recent findings of OPUS II trial 
which suggested that the lack of superior effect of 5-year extended intervention might partly be 
attributable to the high quality of standard community care provided to the control group.15 Fourth, 
the potential disruptive effects of transfer of care from specialised early intervention to generic 
service, with subsequent withdrawal of case management and change of clinician for psychiatric 
follow-up, would likely lead to patients’ perceived sense of loss,7 diminished treatment alliance10 
and limited care coordination with significantly reduced multidisciplinary inputs. This may thus 
result in functional deterioration. In fact, our findings are partially in keeping with this postulation 
as functional decline in various domains, in particular immediate and extended social networks of 
our cohort over the 2-year post-trial period mainly took place in the first year after service 
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termination. A recent naturalistic study further revealed that extended continuity of care up to 5 
years with lower treatment intensity after initial 2-year intensive specialised intervention prevented 
loss of therapeutic gains on symptom and functional outcomes at 5-year follow-up in first-episode 
psychosis patients.39 Fifth, it is plausible that the comparatively briefer DUP (median DUP: 13 
weeks) of our cohort might obscure the potential differential effects of extended intervention on 
longer-term outcomes between patients with short and prolonged untreated initial psychosis. 
Evidence from a recent RCT (RAISE study in United States) has demonstrated that among first-
episode psychosis patients who were allocated to 2-year comprehensive treatment programme, 
those with shorter DUP had significantly better symptom outcome and quality of life at 2-year 
follow-up than the counterparts with prolonged DUP and those randomised to standard care.40 
Reassessment of the RAISE study cohort will help clarify whether such differential treatment effect 
on patients with varying DUP would be critical in determining the durability of therapeutic benefits 
achieved by early intervention service.   
 
    The strengths of the study included low dropout rate (89.4% of the initial cohort completed 3-
year follow-up assessment), lack of differential attrition between treatment groups, masking of 
research staff assessing outcomes to treatment allocation, comprehensive evaluation of functional 
outcomes encompassing both global functioning and various specific functional dimensions, and 
availability of complete clinical record data regarding medication treatment, service use and other 
clinical variables for all participants. Several methodological limitations, however, warrant 
consideration in interpreting the study results. First, as the sample was recruited from the EASY 
programme, which treated patients aged 15-25 years only, our results may not be generalisable to 
people who are older at onset of psychosis. Second, data regarding the inputs of community 
psychiatric care and clinical psychologists after transition to generic service were not available, and 
thus precluded us from estimating the potential confounding effect of enhanced community service 
and provision of CBT on clinical and functional outcomes at post-trial follow-up.  
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        This was the first RCT follow-up study examining the durability of treatment effects of 
extending an early intervention service for psychosis beyond 2 years. Our results indicate that 
superior symptom and functional outcomes attained by 3-year extended early intervention (versus 
2-year early intervention) were not sustained after service withdrawal, even though initial 
improvement in some functional domains seem to be largely maintained during post-trial follow-up. 
Aside from a genuine lack of efficacy of specialised intervention on maintaining positive effects in 
first-episode psychosis patients, an absence of significant outcome difference between treatment 
groups at post-trial follow-up might also be attributable to an array of factors, which nonetheless, 
could not be adequately addressed by the current study. Further investigation is warranted to clarify 
the roles of treatment delay, treatment intensity levels (e.g. case-load per case manager) and length 
of specialised service (e.g. 5-year intensive programme or extended continuity of care by a step-
down service with lower treatment intensity) in determining the sustainability of early intervention 
on outcome improvement. Given the heterogeneous outcome trajectories in first-episode psychosis, 
a universal provision of specialised service to all patients for an extended period might not be the 
most cost-effective approach in optimising long-term outcome. Future research is required to 
identify a subgroup of patients who may benefit most from extended intervention. More studies 
should also be conducted to delineate which specific treatment elements, from an integrated, multi-
component early intervention service, should be offered for an extended duration so as to maintain 
longer-term therapeutic benefits.  
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Fig. 1 Flow of patients through the study. 
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Fig. 2 Longitudinal change in functioning scores across 3-year follow-up in the extended early intervention and step-down care 
control groups: (a) change in Social and Occupational Functioning Assessment Scale (SOFAS) score; (b) change in Role Functioning 
Scale (RFS) total score; (c) change in RFS sub-domains score. 
*P<0.05 
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Table 1 Functional outcomes at 1, 2 and 3-year follow-up of the two study groupsa 
 Intervention group Control group Estimated mean differencea 
(95% CI) P Variables  mean (s.d.) mean (s.d.) 
SOFAS score      
   1-yr follow-up 64.8 (13.1) 57.9 (12.7) 3.57 (1.14 – 5.99) 0.004 
   2-yr follow-up 63.3 (13.6) 59.6 (12.1) 1.28 (-0.31 – 2.88) 0.113 
   3-yr follow-up 64.8 (13.7) 61.9 (12.5) -1.11 (-1.04 – 3.27) 0.311 
RFS work productivity      
   1-yr follow-up 5.1 (1.4) 4.7 (1.5) 0.44 (-0.16 – 0.72) 0.002 
   2-yr follow-up 4.9 (1.5) 4.8 (1.4) 0.15 (-0.01 – 0.30) 0.060 
   3-yr follow-up 5.1 (1.5) 4.9 (1.4) 0.17 (-0.07 – 0.41) 0.173 
RFS independent living      
   1-yr follow-up 6.5 (0.6) 6.2 (1.0) 0.23 (0.06 – 0.39) 0.007 
   2-yr follow-up 6.5 (0.5) 6.3 (0.7) 0.11 (0.01 – 0.23) 0.071 
   3-yr follow-up 6.4 (0.6) 6.3 (0.7) 0.08 (-0.02 – 0.18) 0.112 
RFS immediate social network      
   1-yr follow-up 5.5 (0.9) 5.1 (1.0) 0.27 (0.07 – 0.47) 0.008 
   2-yr follow-up 5.3 (0.8) 5.1 (0.9) 0.15 (-0.04 – 0.34) 0.117 
   3-yr follow-up 5.3 (0.9) 5.0 (1.0) 0.08 (-0.01 – 0.17) 0.059 
RFS extended social network      
   1-yr follow-up 4.9 (1.0) 4.3 (1.3) 0.20 (0.04 – 0.45) 0.010 
   2-yr follow-up 4.8 (0.9) 4.5 (1.1) 0.08 (-0.06 – 0.22) 0.268 
   3-yr follow-up 4.7 (0.9) 4.7 (1.0) 0.01 (-0.21 – 0.20) 0.959 
RFS total score      
   1-yr follow-up 22.1 (3.2) 20.3 (3.7) 1.16 (0.59 – 1.74) < 0.001 
   2-yr follow-up 21.5 (3.3) 20.7 (3.2) 0.44 (-0.13 – 1.01) 0.126 
   3-yr follow-up 21.5 (3.2) 20.9 (3.2) 0.35 (-0.23 – 0.95) 0.251 
CI, confidence interval; RFS, Role Functioning Scale; SOFAS, Social and Occupational Functioning Assessment 
Scale. 
a Estimated mean difference and P values were derived from linear mixed models for repeated measurements (at 
baseline, at 6-month, 1-year, 2-year and 3-year follow-up). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Clinical and service use outcomes of the two study groups during 2-year post-trial  follow-up period 
Variables  Intervention group Control group  t or χ2 P  
Symptom severity at follow-upa, mean (s.d.)     
   PANSS positive symptom score     
      2-year follow-up  10.1 (3.7) 10.3 (3.7) -0.5 0.649 
      3-year follow-up  9.9 (3.4) 10.2 (3.6) -0.6 0.577 
   PANSS negative symptom score     
      2-year follow-up  12.1 (5.1) 11.3 (4.5) 0.9 0.355 
      3-year follow-up  12.0 (4.0) 11.9 (4.0) 0.1 0.941 
   PANSS general psychopathology score     
       2-year follow-up  21.3 (4.3) 21.9 (4.0) -0.9 0.364 
       3-year follow-up  21.2 (5.4) 22.1 (4.6) -1.0 0.304 
   CDS total score     
       2-year follow-up 1.7 (2.3) 2.7 (2.9) -2.3 0.024 
       3-year follow-up  1.6 (2.3) 2.0 (2.8) -1.1 0.271 
Service use outcomes during follow-upb     
   Psychiatric hospital admission, % (n) 17.1 (14) 16.7 (13) 0.0 0.945 
   Length of hospital stay, days: mean (s.d.) 131.5(139.7) 174.3(259.0) 0.5 0.594 
   Default in outpatient appointment, % (n) 31.7 (26) 41. (32) 1.502 0.220 
   Service disengagement, % (n) 6.1 (5) 7.7 (6) 0.2c 0.762 
Other outcome measure during follow-up     
   Relapse of psychotic episodeb, % (n) 25.6 (21) 37.2 (29) 2.5 0.115 
   All-cause mortalityb, % (n) 1.2 (1) 3.8 (3) 1.1c 0.358 
   Suicideb, % (n) 1.2 (1) 1.3 (1) 0.0c 1.000 
   Total months in full-time worka, mean (s.d.) 12.9 (10.0) 11.8 (10.1) 0.6 0.519 
   Full-time work at 3-year follow-upa, % (n) 56.6 (43) 46.3 (31) 1.6 0.218 
Treatment characteristics at follow-upb     
   Antipsychotic treatment at 2-year follow-up, % (n)     
      Not on antipsychotic 16.0 (13) 6.6 (5) 3.6c 0.181 
      Use of FGA 8.6 (7) 7.9 (6)   
      Use of SGA 75.3 (61) 85.5 (65)   
   Antipsychotic treatment at 3-year follow-up, % (n)     
      Not on antipsychotic 11.1 (9) 12 (9) 0.23c 0.911 
      Use of FGA 8.6 (7) 6.7 (5)   
      Use of SGA 80.2 (65) 81.3 (61)   
   CPZ equivalent dose, mg: mean (s.d.)     
      2-year follow-up 333.3 (344.2) 308.2 (290.6) 0.5 0.584 
      3-year follow-up 364.9 (281.0) 296.5 (261.7) 1.5 0.142 
CDS, Calgary Depression Scale; CPZ, chlorpromazine; FGFA, first-generation antipsychotic; PANSS, Positive and 
Negative Syndrome Scale; SGA, second-generation antipsychotic. 
a
 71 participants in intervention group and 67 participants in control group were assessed at 2-year follow-up. 76 
participants in intervention group and 67 participants in control group were assessed at 3-year follow-up. 
b Complete clinical record data were available for all participants. 
c
 Fisher’s exact test was applied as the assumption of chi-square test was not met. 
 
